BeOne Medicines (ONC) stock gains as the FDA grants priority review for cancer therapy Brukinsa in newly diagnosed mantle cell lymphoma. Read more here.
Tipranks Press Release.
Oncology-focused biotech firm BeOne pops into in buy range.
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2026 investor letter for the “Baird Chautauqua International and Global Growth Fund”. The letter can be downloaded here. The broad equity markets posted modest gains in the third quarter, despite significant volatility and rotation beneath the surface. […]
Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.
Beijing is attempting to have at least five pharmaceutical products with annual global sales of more than US$1 billion.
BeOne Medicines, a global oncology company, today announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for TEVIMBRA® (tislelizumab for injection) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA...
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne’s positioning in cancer care and its cost base in a key...
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 […]
On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on Phase 3 data showing patients lived a median of 26.4 months, more than two years, […]
SAN CARLOS, Calif., September 01, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT.
Trump unveils new drug-pricing deals with pharma and biotechs to cut U.S. healthcare costs, with Medicaid most-favored-nation pricing.
SAN CARLOS, Calif., August 31, 2026--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scient
BeOne Medicines (ONC) voluntarily agreed with the US government to expand patient access to its canc
Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.
Jazz Pharmaceuticals (JAZZ) stock rises as the FDA approves the company's cancer therapy developed with BeOne Medicines (ONC) and Zymeworks (ZYME). Read more here.
Is it a good or bad thing when a stock experiences a golden cross technical event?
This is the newest page. Registered accounts read further back.